FCM
ZNTL icon

Farallon Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Farallon Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-991,174
Closed -$32.4M – 152
2020
Q3 		$32.4M Hold
991,174
– – 0.22% 76
2020
Q2 		$47.6M Buy
+991,174
New +$38M 0.38% 57

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Farallon Capital Management's ZNTL Position: Q4 2020 in Review

Farallon Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2020, closing a stake of 991,174 shares — an estimated $32.4M sold.

Farallon Capital Management first reported a position in ZNTL in Q2 2020 and held it in 2 quarters. The position peaked at $47.6M in Q2 2020. 107 funds tracked by Wall St. Rank hold ZNTL as of Q4 2020.

  • Farallon Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Farallon Capital Management sold 991,174 Zentalis Pharmaceuticals shares in Q4 2020, an estimated $32.4M.
  • Farallon Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Farallon Capital Management's Zentalis Pharmaceuticals position peaked at $47.6M in Q2 2020.
  • 107 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2020.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.